Eureka Therapeutics Adds Stanford Liver Cancer Expert Dr. Samuel So to Scientific Advisory Board

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Samuel So, MBBS, FACS, a globally recognized leader in liver cancer surgery, prevention, and health policy at Stanford University, to its Scientific Advisory Board. Dr. So will provide strategic guidance as Eureka advances its ARTEMIS® CAR-T platform and clinical programs targeting hepatocellular carcinoma